The week in pharma: action, reaction and insight – week to June 30, 2023

2 July 2023

By Barbara Obstoj-Cardwell. Editor

Research news last included Germany’s Boehringer Ingelheim and Danish partner Zealand Pharma releasing weight loss results for their candidate survodutide (BI 456906) and US pharma giant Pfizer announcing it would drop development of lotiglipron as a potential treatment for obesity and type 2 diabetes, instead focussing on danuglipron. Also of note, US biopharma Intercept Pharmaceuticals announced another setback for its obeticholic acid (OCA) in pre-cirrhotic liver fibrosis due to non-alcoholic steatohepatitis (NASH), causing the company to give up on the drug in this indication. Eli Lilly revealed plans to acquire Sigilon Therapeutics, and its diabetes candidate SIG-002, for around $310 million, with a modest $34.6 million upfront. On the regulatory front, US biotech BioMarin gained US Food and Drug Administration (FDA) approval for Roctavian, its gene therapy for severe hemophilia A.

Toxicity undermines Boehringer and Zealand’s incretin

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK